 SOUTH SAN FRANCISCO, Calif., June 18, 2021 GLOBE NEWSWIRE -- RAPT Therapeutics, Inc. Nasdaq: RAPT, a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the closing of its previously announced underwritten public offering of 4,356,060 shares of its common stock at a price to the public of 33.00 per share, which includes 568,181 shares issued and sold upon full exercise of the underwriters option to purchase additional shares of common stock. All of the shares of common stock were offered by RAPT. The aggregate gross proceeds to RAPT from the offering were approximately 143.7 million, before deducting underwriting discounts and commissions and other offering expenses. 